Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-6
Closed -$454 425
2026
Q1
$454 Hold
6
﹤0.01% 316
2025
Q4
$447 Sell
6
-1
-14% -$73 ﹤0.01% 320
2025
Q3
$472 Sell
7
-3
-30% -$199 ﹤0.01% 321
2025
Q2
$652 Buy
10
+1
+11% +$60 ﹤0.01% 251
2025
Q1
$556 Buy
9
+6
+200% +$398 ﹤0.01% 265
2024
Q4
$216 Hold
3
﹤0.01% 248
2024
Q3
$244 Hold
3
﹤0.01% 267
2024
Q2
$223 Sell
3
-1
-25% -$75 ﹤0.01% 252
2024
Q1
$312 Hold
4
﹤0.01% 200
2023
Q4
$286 Buy
4
+1
+33% +$70 ﹤0.01% 201
2023
Q3
$208 Buy
+3
New +$227 ﹤0.01% 225
2023
Q1
Sell
-3
Closed -$242 215
2022
Q4
$224 Hold
3
﹤0.01% 219
2022
Q3
$0 Hold
3
﹤0.01% 227
2022
Q2
$207 Buy
+3
New +$223 ﹤0.01% 216
2022
Q1
Sell
-2
Closed -$144 258
2021
Q4
$153 Buy
+2
New +$147 ﹤0.01% 293
2021
Q3
Hold
0
286
2021
Q2
Hold
0
296

Other funds holding HOLX

WestEnd Advisors's HOLX Position: Q2 2026 in Review

WestEnd Advisors sold out of Hologic (HOLX) in Q2 2026, closing a stake of 6 shares — an estimated $454 sold.

WestEnd Advisors first reported a position in HOLX in Q4 2021 and held it in 15 quarters. The position peaked at $652 in Q2 2025. 3 funds tracked by Wall St. Rank hold HOLX as of Q2 2026.

  • WestEnd Advisors reported no remaining Hologic position as of Q2 2026 after selling out during the quarter.
  • WestEnd Advisors sold 6 Hologic shares in Q2 2026, an estimated $454.
  • WestEnd Advisors first reported a position in Hologic in Q4 2021 and held it in 15 quarters.
  • WestEnd Advisors's Hologic position peaked at $652 in Q2 2025.
  • 3 funds tracked by Wall St. Rank held Hologic as of Q2 2026.

Based on WestEnd Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.